A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

Study Purpose

The purpose of this study is to compare the efficacy of JNJ-68284528 with standard therapy, either Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd).

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Measurable disease at screening as defined by any of the following: (a) Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL) or urine M-protein level >=200 milligram (mg)/24 hours; or (b) Light chain multiple myeloma without measurable M-protein in the serum or the urine: Serum free light chain >=10 mg/dL and abnormal serum free light chain ratio.
  • - Have received 1 to 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) - Have documented evidence of PD by International Myeloma Working Group (IMWG) criteria based on investigator's determination on or within 6 months of their last regimen.
  • - Be refractory to lenalidomide per IMWG consensus guidelines (failure to achieve minimal response or progression on or within 60 days of completing lenalidomide therapy).
Progression on or within 60 days of the last dose of lenalidomide given as maintenance will meet this criterion. For participants with more than 1 prior line of therapy, there is no requirement to be lenalidomide refractory to the most recent line of prior therapy.
  • - Have clinical laboratory values meeting the following criteria during the Screening Phase (re testing is allowed but the below criteria must be met in the latest test prior to randomization): 1.
Hemoglobin >=8 gram per deciliter (g/dL) (without prior RBC transfusion within 7 days before the laboratory test; recombinant human erythropoietin use is permitted); 2. Absolute neutrophil count (ANC) >=1 * 10^9 per liter (L) (without recombinant human granulocyte colony-stimulating factor [G-CSF] within 7 days and without pegylated G-CSF within 14 days of the laboratory test); 3. Platelet count >=75 * 10^9/L (without prior platelet transfusion within 7 days before the laboratory test) in subjects in whom less than (<) 50 percent (%) of bone marrow nucleated cells are plasma cells; platelet count >=50 * 10^9/L (without prior platelet transfusion within 7 days before the laboratory test) in subjects in whom >=50% of bone marrow nucleated cells are plasma cells; 4. Lymphocyte count >=0.3 * 10^9/L; 5. Aspartate aminotransferase (AST) less than or equal to (<=)3 * upper limit of normal (ULN); 6. Alanine aminotransferase (ALT) <=3 * ULN; 7. Total bilirubin <=2.0 * ULN; except in subjects with congenital bilirubinemia, such as Gilbert syndrome (in which case direct bilirubin <=1.5 * ULN is required); 8. Estimated glomerular filtration rate >=40 milliliter per minute (mL/min) per 1.73 meter square (m^2) (to be calculated using the Modification of Diet in Renal Disease [MDRD] formula)

Exclusion Criteria:

  • - Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy directed at any target.
  • - Any previous therapy that is targeted to B-cell maturation antigen (BCMA) - Ongoing toxicity from previous anticancer therapy that has not resolved to baseline levels or to Grade 1 or less; except for alopecia.
  • - Participants with Grade 1 peripheral neuropathy with pain or Grade 2 or higher peripheral neuropathy will not be permitted to receive pomalidomide, bortezomib, and dexamethasone (PVd) as standard therapy or bridging therapy; however, participant may receive daratumumab, pomalidomide, and dexamethasone (DPd) as standard therapy or bridging therapy.
  • - Received a cumulative dose of corticosteroids equivalent to >=70 mg of prednisone within the 7 days prior to randomization.
  • - Monoclonal antibody treatment within 21 days.
  • - Cytotoxic therapy within 14 days.
  • - Proteasome inhibitor therapy within 14 days.
- Immunomodulatory drug (IMiD) therapy within 7 days

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04181827
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Janssen Research & Development, LLC
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Janssen Research & Development, LLC Clinical Trial
Principal Investigator Affiliation Janssen Research & Development, LLC
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Australia, Austria, Belgium, Denmark, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Spain, Sweden, United Kingdom, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Multiple Myeloma
Study Website: View Trial Website
Additional Details

Multiple myeloma is a malignant plasma cell disorder diagnosed annually in approximately 86,000 participants worldwide. JNJ-68284528 is an autologous chimeric antigen receptor T-cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA), a molecule expressed on the surface of mature B lymphocytes and malignant plasma cells. The primary hypothesis for this study is that JNJ-68284528 will significantly improve progression free survival (PFS) compared with standard therapy (PVd or DPd), in participants who have previously received 1 to 3 prior line(s) of therapy, that included a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) and who are refractory to lenalidomide. This study will be conducted in 3 phases: Screening (up to 28 days before randomization), Treatment, and Follow-Up. Assessment like patient-reported outcome(s) (PROs) assessments, electrocardiogram (ECG), vital signs, pharmacokinetic will be performed during the study. Safety evaluations will include review of adverse events, laboratory test results, vital sign measurements, physical examination findings, and assessments of cardiac function, Immune Effector Cell-associated Encephalopathy (only for Arm B) and Eastern Cooperative Oncology Group performance status. Safety data will be periodically reviewed by an Independent Data Monitoring Committee (IDMC). The duration of the study is approximately 6 years.

Arms & Interventions

Arms

Experimental: Arm A: PVd or DPd (Standard Therapy)

Participants will receive either PVd or DPd as a standard therapy. In PVd treatment, participants will receive oral pomalidomide 4 mg on Days 1 to 14 in each cycle; bortezomib 1.3 mg/meter square (m^2) SC on Days 1, 4, 8 and 11 (Cycles 1 to 8) and on Days 1 and 8 (Cycle 9 onwards) and oral dexamethasone 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 (Cycles 1 to 8) and Days 1, 2, 8 and 9 (Cycle 9 onwards). Each cycle will consist of 21 days. In DPd treatment, participants will receive daratumumab SC 1800 mg weekly on Days 1, 8, 15, and 22 (Cycles 1 and 2), every 2 weeks on Days 1 and 15 (Cycles 3 to 6) and every 4 weeks on Day 1 (Cycle 7 onwards); oral pomalidomide 4 mg on Days 1 to 21 (Cycle 1 onwards); dexamethasone 40 mg oral or IV weekly on Days 1, 8, 15, and 22 (Cycle 1 onwards). Each cycle will consist of 28 days. Participants will continue to receive PVd or DPd until confirmed PD, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs earlier.

Experimental: Arm B: JNJ-68284528

Participants will receive one cycle of bridging therapy (PVd or DPd) and additional cycles of bridging therapy may be considered based on participant's clinical status and timing of availability of JNJ-68284528 along with conditioning regimen (cyclophosphamide 300 milligram [mg]/m^2 intravenous [IV] and fludarabine 30 mg/m^2 IV daily, for 3 days), and JNJ-68284528 infusion 0.75 * 10^6 chimeric antigen receptor (CAR)-positive viable T cells/ kilogram (kg).

Interventions

Drug: - JNJ-68284528

JNJ-68284528 infusion will be administered at a target dose of 0.75 * 10^6 CAR-positive viable T cells/kilogram (kg).

Drug: - Pomalidomide

Pomalidomide 4 mg will be administered orally.

Drug: - Bortezomib

Bortezomib 1.3 milligram per meter square (mg/m^2) will be administered subcutaneously (SC).

Drug: - Dexamethasone

Dexamethasone 20 mg/day (10mg/day for participants >75 years of age) (on bortezomib treatment days and the days following bortezomib treatment) will be administered orally in PVd treatment; and orally or intravenous (IV) at 40 mg weekly (20mg weekly for participants >75 years of age) in DPd treatment.

Drug: - Daratumumab

Daratumumab 1800 mg will be administered SC.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

University of Alabama at Birmingham, Birmingham, Alabama

Status

Recruiting

Address

University of Alabama at Birmingham

Birmingham, Alabama, 35294

Mayo Clinic Cancer Center-Scottsdale, Phoenix, Arizona

Status

Not yet recruiting

Address

Mayo Clinic Cancer Center-Scottsdale

Phoenix, Arizona, 85054

Stanford University Medical Center, Stanford, California

Status

Recruiting

Address

Stanford University Medical Center

Stanford, California, 94305-5623

Colorado Blood Cancer Institute, Denver, Colorado

Status

Recruiting

Address

Colorado Blood Cancer Institute

Denver, Colorado, 80218

Yale New Haven Hospital, New Haven, Connecticut

Status

Recruiting

Address

Yale New Haven Hospital

New Haven, Connecticut, 06520

Miami, Florida

Status

Recruiting

Address

University of Miami Leonard M. Miller School of Medicine - Sylvester Comprehensive Cancer Center

Miami, Florida, 33136-1002

Emory University, Atlanta, Georgia

Status

Not yet recruiting

Address

Emory University

Atlanta, Georgia, 30322

Northside Hospital Cancer Institute, Atlanta, Georgia

Status

Withdrawn

Address

Northside Hospital Cancer Institute

Atlanta, Georgia, 30342

University of Iowa Hospitals & Clinics, Iowa City, Iowa

Status

Recruiting

Address

University of Iowa Hospitals & Clinics

Iowa City, Iowa, 52242

University of Kansas, Westwood, Kansas

Status

Recruiting

Address

University of Kansas

Westwood, Kansas, 66205

University Of Maryland Medical Center, Baltimore, Maryland

Status

Not yet recruiting

Address

University Of Maryland Medical Center

Baltimore, Maryland, 21201

University of Michigan Health System, Ann Arbor, Michigan

Status

Not yet recruiting

Address

University of Michigan Health System

Ann Arbor, Michigan, 48109

University Of Minnesota, Minneapolis, Minnesota

Status

Withdrawn

Address

University Of Minnesota

Minneapolis, Minnesota, 55455

Mayo Clinic - Rochester, Rochester, Minnesota

Status

Not yet recruiting

Address

Mayo Clinic - Rochester

Rochester, Minnesota, 55905

Washington University School of Medicine, Saint Louis, Missouri

Status

Recruiting

Address

Washington University School of Medicine

Saint Louis, Missouri, 63110

Hackensack University Medical Center, Hackensack, New Jersey

Status

Recruiting

Address

Hackensack University Medical Center

Hackensack, New Jersey, 07601

Memorial Sloan-Kettering Cancer Center, New York, New York

Status

Recruiting

Address

Memorial Sloan-Kettering Cancer Center

New York, New York, 10065

University of Rochester Medical Center, Rochester, New York

Status

Recruiting

Address

University of Rochester Medical Center

Rochester, New York, 14642

Duke University Medical Center, Durham, North Carolina

Status

Not yet recruiting

Address

Duke University Medical Center

Durham, North Carolina, 27710

Cleveland Clinic, Cleveland, Ohio

Status

Withdrawn

Address

Cleveland Clinic

Cleveland, Ohio, 44195

The Ohio State University, Columbus, Ohio

Status

Recruiting

Address

The Ohio State University

Columbus, Ohio, 43210

Sarah Cannon Research Institute, Nashville, Tennessee

Status

Not yet recruiting

Address

Sarah Cannon Research Institute

Nashville, Tennessee, 37203

Huntsman Cancer Institute, Salt Lake City, Utah

Status

Recruiting

Address

Huntsman Cancer Institute

Salt Lake City, Utah, 84112

Madison, Wisconsin

Status

Not yet recruiting

Address

University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53792

Medical College Of Wisconsin, Milwaukee, Wisconsin

Status

Recruiting

Address

Medical College Of Wisconsin

Milwaukee, Wisconsin, 53226

International Sites

Royal Adelaide Hospital, Adelaide, Australia

Status

Recruiting

Address

Royal Adelaide Hospital

Adelaide, , 5000

Royal Prince Alfred Hospital, Camperdown, Australia

Status

Recruiting

Address

Royal Prince Alfred Hospital

Camperdown, , 2050

Royal Brisbane and Womens Hospital, Herston, Australia

Status

Recruiting

Address

Royal Brisbane and Womens Hospital

Herston, , 4029

Alfred Health, Melbourne, Australia

Status

Recruiting

Address

Alfred Health

Melbourne, , 3004

Peter MacCallum Cancer Centre, Melbourne, Australia

Status

Recruiting

Address

Peter MacCallum Cancer Centre

Melbourne, , 8006

Fiona Stanley Hospital, Murdoch, Australia

Status

Recruiting

Address

Fiona Stanley Hospital

Murdoch, , 6150

Calvary Mater Newcastle Hospital, Waratah, Australia

Status

Not yet recruiting

Address

Calvary Mater Newcastle Hospital

Waratah, , 2298

Western Sydney Local Health District, Westmead, Australia

Status

Not yet recruiting

Address

Western Sydney Local Health District

Westmead, , 2145

Vienna, Austria

Status

Not yet recruiting

Address

Medical University of Vienna,Universitätsklinik für Innere Medizin I

Vienna, , 1090

Universitair Ziekenhuis - Antwerpen, Antwerp, Belgium

Status

Recruiting

Address

Universitair Ziekenhuis - Antwerpen

Antwerp, , 2650

Institut Jules Bordet, Brussel, Belgium

Status

Withdrawn

Address

Institut Jules Bordet

Brussel, , 1000

UZ Gent, Gent, Belgium

Status

Recruiting

Address

UZ Gent

Gent, , 9000

UZ Leuven, Leuven, Belgium

Status

Recruiting

Address

UZ Leuven

Leuven, , 3000

Liege, Belgium

Status

Recruiting

Address

Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman

Liege, , B-4000

Rigshospitalet, Copenhagen, Denmark

Status

Recruiting

Address

Rigshospitalet

Copenhagen, , 2100

CHRU de Lille - Hôpital Claude Huriez, LILLE Cedex, France

Status

Recruiting

Address

CHRU de Lille - Hôpital Claude Huriez

LILLE Cedex, , 59037

CHU de Montpellier, Hopital Saint-Eloi, Montpellier, France

Status

Not yet recruiting

Address

CHU de Montpellier, Hopital Saint-Eloi

Montpellier, , 34295

C.H.U. Hotel Dieu - France, Nantes, France

Status

Recruiting

Address

C.H.U. Hotel Dieu - France

Nantes, , 44093

Hopital Saint-Louis, Paris cedex 10, France

Status

Not yet recruiting

Address

Hopital Saint-Louis

Paris cedex 10, , 75475

CHU de Bordeaux - Hôpital Haut-Lévêque, Pessac cedex, France

Status

Withdrawn

Address

CHU de Bordeaux - Hôpital Haut-Lévêque

Pessac cedex, , 33604

Centre hospitalier Lyon-Sud, Pierre Benite cedex, France

Status

Recruiting

Address

Centre hospitalier Lyon-Sud

Pierre Benite cedex, , 69495

CHU De Poitiers, Poitiers, France

Status

Recruiting

Address

CHU De Poitiers

Poitiers, , 86021

Toulouse cedex 9, France

Status

Not yet recruiting

Address

Institut Universitaire du cancer de Toulouse-Oncopole

Toulouse cedex 9, , 31059

Dresden, Germany

Status

Recruiting

Address

Universitatsklinikum Carl Gustvav Carus Dresden an der Technischen Universitat Dresden

Dresden, , 01307

Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany

Status

Not yet recruiting

Address

Universitaetsklinikum Hamburg Eppendorf

Hamburg, , 20246

Universitaetsklinikum Heidelberg, Heidelberg, Germany

Status

Not yet recruiting

Address

Universitaetsklinikum Heidelberg

Heidelberg, , 69120

Universitaetsklinikum Koeln, Köln, Germany

Status

Not yet recruiting

Address

Universitaetsklinikum Koeln

Köln, , 50924

Universitatsklinikum Leipzig, Leipzig, Germany

Status

Not yet recruiting

Address

Universitatsklinikum Leipzig

Leipzig, , 04103

Tübingen, Germany

Status

Not yet recruiting

Address

Klinikum der Eberhard-Karls-Universität/Abt. für innere Med. II/Hämatologie/Onkologie-Germany

Tübingen, , 72076

Universitätsklinikum Würzburg, Würzburg, Germany

Status

Not yet recruiting

Address

Universitätsklinikum Würzburg

Würzburg, , 97080

Athens, Greece

Status

Not yet recruiting

Address

Attikon University General Hospital of Attica

Athens, , 12462

Hadassah University Hospita - Ein Kerem, Jerusalem, Israel

Status

Not yet recruiting

Address

Hadassah University Hospita - Ein Kerem

Jerusalem, , P.O.B. 12000

Sheba Medical Center, Ramat Gan, Israel

Status

Recruiting

Address

Sheba Medical Center

Ramat Gan, , 74047

Sourasky Medical Center, Tel-Aviv, Israel

Status

Recruiting

Address

Sourasky Medical Center

Tel-Aviv, , 64239

Policlinico Sant'Orsola Malpighi, Bologna, Italy

Status

Recruiting

Address

Policlinico Sant'Orsola Malpighi

Bologna, , 40138

Milano, Italy

Status

Not yet recruiting

Address

Ospedale San Raffaele HSR Istituto Scientifico Universitario San Raffaele

Milano, , 20132

Milano, Italy

Status

Recruiting

Address

Fondazione IRCCS Istituto Nazionale dei Tumori

Milano, , 20133

Roma, Italy

Status

Recruiting

Address

Policlinico Universitario Agostino Gemelli

Roma, , 00168

Turin, Italy

Status

Recruiting

Address

A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette

Turin, , 10126

Kyushu University Hospital, Fukuoka, Japan

Status

Recruiting

Address

Kyushu University Hospital

Fukuoka, , 812-8582

Kanazawa University Hospital, Kanazawa, Japan

Status

Recruiting

Address

Kanazawa University Hospital

Kanazawa, , 920-8641

Kyoto, Japan

Status

Recruiting

Address

University Hospital Kyoto Perfectural University of Medicine

Kyoto, , 602-8566

Nagoya City University Hospital, Nagoya, Japan

Status

Recruiting

Address

Nagoya City University Hospital

Nagoya, , 467-8602

Okayama University Hospital, Okayama, Japan

Status

Recruiting

Address

Okayama University Hospital

Okayama, , 700-8558

Hokkaido University Hospital, Sapporo, Japan

Status

Recruiting

Address

Hokkaido University Hospital

Sapporo, , 060-8648

Tohoku University Hospital, Sendai, Japan

Status

Recruiting

Address

Tohoku University Hospital

Sendai, , 980-8574

Japanese Red Cross Medical Center, Shibuya, Japan

Status

Recruiting

Address

Japanese Red Cross Medical Center

Shibuya, , 150-8935

Samsung Medical Center, Seoul, Korea, Republic of

Status

Recruiting

Address

Samsung Medical Center

Seoul, , 06351

Seoul, Korea, Republic of

Status

Recruiting

Address

The Catholic University of Korea Seoul St. Mary's Hospital

Seoul, , 06591

Seoul National University Hospital, Seoul, Korea, Republic of

Status

Recruiting

Address

Seoul National University Hospital

Seoul, , 3080

VU Medisch Centrum, Amsterdam, Netherlands

Status

Recruiting

Address

VU Medisch Centrum

Amsterdam, , 1081 HV

University Medical Center Groningen, Groningen, Netherlands

Status

Recruiting

Address

University Medical Center Groningen

Groningen, , 9713 GZ

Erasmus MC, Rotterdam, Netherlands

Status

Recruiting

Address

Erasmus MC

Rotterdam, , 3015 CN

UMC Utrecht, Utrecht, Netherlands

Status

Recruiting

Address

UMC Utrecht

Utrecht, , 3584 CX

Uniwersyteckie Centrum Kliniczne, Gdansk, Poland

Status

Recruiting

Address

Uniwersyteckie Centrum Kliniczne

Gdansk, , 80-952

Gliwice, Poland

Status

Recruiting

Address

Narodowy Instytut Onkologii im.Marii Sklodowskiej Curie Panstwowy Instytut BadawczyOddz. w Gliwicach

Gliwice, , 44102

Poznan, Poland

Status

Recruiting

Address

Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego

Poznan, , 60-569

Instytut Hematologii i Transfuzjologii, Warszawa, Poland

Status

Recruiting

Address

Instytut Hematologii i Transfuzjologii

Warszawa, , 02-776

Inst. Cat. D'Oncologia-Badalona, Badalona, Spain

Status

Recruiting

Address

Inst. Cat. D'Oncologia-Badalona

Badalona, , 08916

Hosp. Clinic I Provincial de Barcelona, Barcelona, Spain

Status

Recruiting

Address

Hosp. Clinic I Provincial de Barcelona

Barcelona, , 08036

Hosp. Gral. Univ. Gregorio Marañon, Madrid, Spain

Status

Not yet recruiting

Address

Hosp. Gral. Univ. Gregorio Marañon

Madrid, , 28007

Hosp. Univ. 12 de Octubre, Madrid, Spain

Status

Recruiting

Address

Hosp. Univ. 12 de Octubre

Madrid, , 28041

Clinica Univ. de Navarra, Pamplona, Spain

Status

Recruiting

Address

Clinica Univ. de Navarra

Pamplona, , 31008

Hosp. Clinico Univ. de Salamanca, Salamanca, Spain

Status

Recruiting

Address

Hosp. Clinico Univ. de Salamanca

Salamanca, , 37007

Hosp. Virgen Del Rocio, Sevilla, Spain

Status

Not yet recruiting

Address

Hosp. Virgen Del Rocio

Sevilla, , 41013

Skane University Hospital, Lund, Sweden

Status

Recruiting

Address

Skane University Hospital

Lund, , 221 85

Stockholm, Sweden

Status

Recruiting

Address

Karolinska Universitetssjukhuset Huddinge, Hematologiska Kliniken, Huddinge

Stockholm, , 141 86

Akademiska Sjukhuset, Uppsala, Sweden

Status

Recruiting

Address

Akademiska Sjukhuset

Uppsala, , 751 85

Queen Elizabeth Hospital, Birmingham, United Kingdom

Status

Not yet recruiting

Address

Queen Elizabeth Hospital

Birmingham, , B15 2TH

Bristol Royal Infirmary, Bristol, United Kingdom

Status

Recruiting

Address

Bristol Royal Infirmary

Bristol, , BS2 8BJ

University Hospital Wales, Cardiff, United Kingdom

Status

Not yet recruiting

Address

University Hospital Wales

Cardiff, , CF14 4XW

University College Hospital, London, United Kingdom

Status

Recruiting

Address

University College Hospital

London, , NW1 2BU

King's College Hospital, London, United Kingdom

Status

Not yet recruiting

Address

King's College Hospital

London, , SE5 9RS

Christie Hospital, Manchester, United Kingdom

Status

Not yet recruiting

Address

Christie Hospital

Manchester, , M20 4BX

Freeman Hospital, Newcastle Upon Tyne, United Kingdom

Status

Recruiting

Address

Freeman Hospital

Newcastle Upon Tyne, , NE7 7DN